🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AstraZeneca Pharma India Limited ASTRAZEN NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.astrazeneca.in
Company Profile ↓
₹8,207.00
-9.61% 1Y
Mkt Cap₹20,517.50 Cr
P/E109.41
P/B23.75
Div. Yield0.39%
52W High₹9,827.50
52W Low₹7,765.50
Book Value₹349.12
EPS (TTM)₹75.01

Company Overview

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 21.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 25.5%.

Consistent Profit Growth

Net profit has compounded at 23.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 31.4% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.13.

Recent Developments

  • Mar 2026 Revenue of ₹2,275.58 Cr (+32.6% YoY); net profit ₹187.52 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +32.6%, earnings +62.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 31.4%, profit CAGR 23.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:31.40%
1 Year:32.59%

Compounded Profit Growth

5 Years:23.61%
1 Year:62.02%

Stock Price Performance

1 Year:-9.61%
6 Months:-2.51%
3 Months:-3.76%
1 Month:-2.57%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 21% of range
₹7,765.50 ₹9,827.50
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)45.37 · Neutral
Price Performance
1M-2.57%
3M-3.76%
6M-2.51%
1Y-9.61%
Valuation vs Sector

P/E of 109.41 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 21.5%.
  • Healthy ROCE of 25.5%.
  • Compounding revenue at 31.4% over 5 years.
  • Profit CAGR of 23.6% over 5 years.

CONS

  • Trading at a high P/E of 109.4.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
109.41
Industry PE
39.97
Forward P/E est.
67.53
PEG Ratio
-
Book Value
₹349.12
Price to Book
23.75
P/S
9.11
EV/EBITDA
77.82
Dividend Yield
0.39%

Growth (CAGR)

Revenue 5Y
31.40%
Profit 5Y
23.61%
Revenue (YoY)
32.59%
Earnings (YoY)
62.02%

Profitability & Returns

ROCE
25.48%
ROE
21.49%
ROA
9.43%
Profit Margin
8.24%
Op Margin
10.26%
Gross Margin
39.33%
EPS (Latest Qtr)
₹17.95
EPS (TTM)
₹75.01

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
0.73
Current Ratio
1.77
Debt
₹110.66 Cr
Total Assets
₹1,989.10 Cr
Current Assets
₹1,739.93 Cr
Working Capital
₹758.12 Cr

Ownership

Promoter Holding
81.58%
Chg in Prom Hold
-
FII / Inst Holding
7.83%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹20,517.50 Cr
Total Revenue (TTM)
₹2,275.58 Cr
EBITDA
₹285.27 Cr
Free Cash Flow
₹-18.75 Cr
Operating Cash Flow
₹-15.14 Cr
Shares Outstanding
₹2.50 Cr
Gross Margin
39.33%
Payout Ratio
42.66%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ASTRAZEN AstraZeneca Pharma India Limited NSEPHARMA 8,207.00 109.41 ₹20,517.50 Cr 0.39% 25.48% 21.49% 31.40% 23.61%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -480.48 Cr526.31 Cr559.09 Cr611.57 Cr578.61 Cr
Cost of Revenue -259.61 Cr295.41 Cr324.49 Cr366.39 Cr394.25 Cr
Gross Profit -220.87 Cr230.90 Cr234.60 Cr245.18 Cr184.36 Cr
Operating Expenses -152.19 Cr166.36 Cr161.99 Cr204.19 Cr129.05 Cr
Operating Income -68.68 Cr64.54 Cr72.61 Cr40.99 Cr55.31 Cr
EBITDA -96.84 Cr91.99 Cr76.06 Cr51.44 Cr65.78 Cr
Interest Expense -68.00 L72.00 L67.00 L1.06 Cr2.04 Cr
Pretax Income -78.47 Cr74.70 Cr72.82 Cr46.54 Cr58.14 Cr
Tax Provision -20.22 Cr18.87 Cr18.60 Cr13.95 Cr13.26 Cr
Net Income -58.25 Cr55.83 Cr54.22 Cr32.59 Cr44.88 Cr
Diluted EPS -23.3022.3321.6913.0417.95

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,002.97 Cr1,295.53 Cr1,716.29 Cr2,275.58 Cr
Cost of Revenue -425.26 Cr673.26 Cr963.01 Cr1,380.54 Cr
Gross Profit -577.71 Cr622.27 Cr753.28 Cr895.04 Cr
Operating Expenses -428.82 Cr450.84 Cr539.30 Cr661.59 Cr
Operating Income -148.89 Cr171.43 Cr213.98 Cr233.45 Cr
EBITDA -150.99 Cr235.68 Cr197.81 Cr285.27 Cr
Interest Expense -63.00 L1.20 Cr1.46 Cr4.49 Cr
Pretax Income -134.10 Cr219.54 Cr156.36 Cr252.20 Cr
Tax Provision -34.81 Cr58.03 Cr40.62 Cr64.68 Cr
Net Income -99.29 Cr161.51 Cr115.74 Cr187.52 Cr
Diluted EPS -39.7064.6046.3075.01

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -984.87 Cr1,078.03 Cr1,518.12 Cr1,989.10 Cr
Current Assets -835.47 Cr932.71 Cr1,342.35 Cr1,739.93 Cr
Cash & Equivalents -500.34 Cr505.57 Cr536.14 Cr447.72 Cr
Inventory -190.21 Cr227.88 Cr548.50 Cr1,027.33 Cr
Receivables -107.52 Cr153.13 Cr184.88 Cr213.68 Cr
Total Liabilities -396.18 Cr366.11 Cr747.77 Cr1,116.31 Cr
Current Liabilities -383.93 Cr357.12 Cr703.00 Cr981.81 Cr
Long Term Debt -----
Total Debt -7.21 Cr4.59 Cr35.73 Cr110.66 Cr
Total Equity -588.69 Cr711.92 Cr770.35 Cr872.79 Cr
Shares Outstanding -2.50 Cr2.50 Cr2.50 Cr2.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -58.29 Cr27.87 Cr65.36 Cr-15.14 Cr
Investing Cash Flow -18.11 Cr21.74 Cr30.80 Cr18.69 Cr
Financing Cash Flow --24.48 Cr-44.38 Cr-65.59 Cr-91.97 Cr
Capital Expenditure --8.52 Cr-10.76 Cr-1.75 Cr-3.61 Cr
Free Cash Flow -49.77 Cr17.11 Cr63.61 Cr-18.75 Cr
Net Change in Cash -51.92 Cr5.23 Cr30.57 Cr-88.42 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -57.6%48.0%43.9%39.3%
Operating Margin % -14.8%13.2%12.5%10.3%
Net Margin % -9.9%12.5%6.7%8.2%
ROE % -16.9%22.7%15.0%21.5%
ROCE % -24.8%23.8%26.3%23.2%

Shareholding Pattern

Insiders
81.58%
Institutions
7.83%
Public Float
42.50%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ASTRAZEN

Google News hu, 09 Jul 2026

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse - CNBC

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPMDQyN2hzSzZrYVFOY3F1RUtzSENYRlUyZk5zaHBZVERYQVY1V0UwN2thZXNqQW5vdXctUFR4emVhVjdSaGt0WjdIMFMwZ1A3LXYzczFpWkJ5TDIxd0E4RGNfYzR1SndVU3lXcm9yUFhZT0c5MExOM0xkRjl5VGJjSS1NN2jSAYoBQVVfeX…

Google News hu, 09 Jul 2026

AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure - Clinical Trials Arena

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPUmhSbmRKVVJQbVRmMmxRd2cteDZoeHdabjEwR0FMdDVtaVVtdXdsQmlJVS1jSG1VMGFSbHBGRnBLcEpuX0lhN3ljZU9ILTZxX09KT2RyTlFKTklkWnMtX2ZiRk1ZbmxfUlN6clR6QlMyYzduandhQ09CWmtTbE52R3d0dFNnVS03YXc5bl…

Google News hu, 09 Jul 2026

AstraZeneca and Ionis Stock Slump After Trial Miss Is an Overreaction - Barron's

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQU3Zla2lxdExtVXVweTBJclR3MldqOXN4bV8zZ0RIa1c2Q0ZDRng4Sm5SVHhvS2dJYUpCR2ZiMmUxcVVmMFhIeGZsUmpwTW81MURLUUJPVVZoSWRRZG5aOHpIWmw4MGNxbXJUMnk0Q0Q2T3NLRDY3MVVrMTdyT1ctOE5vaDFSZVMzVHlYaV…

Google News hu, 09 Jul 2026

Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOc1lPYXlqVWlSVHYwaV8xLTM0M1paYi1nRUJmRUtTa20tUkdoVHY4amZGU2VmNXAtY0syX2xyOGRvZDBjbDRyeU45RFROMmY2TW9rbTI0TWJjZ3dqWklxNFo5MmZVd3d3V1FRa3hnN0ZfZ2lGTFdYTkxieGZVeHZnSXEtckRfaDhyUFJ1Uz…

Google News hu, 09 Jul 2026

AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial - WSJ

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPU0dSaVRkN2pmY3lURW10RzVwYlRRNFFfcW90Vmg3SVRiUXFpTG1ON25fdWNsR1ZJdXNJS3NSQ1gwYVdNaDhfRzlZTnRyTGY0M1l6UGxQS1BrZnQxZTN4bE1rak1zNGJtMzRMcUVCbVlzWVlmTHBWeXdxb01iVFJtZWFGbTJkeGczVk12Y2…

Google News hu, 09 Jul 2026

AstraZeneca sees stock market value slump by more than £20bn after drug setback - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOZGI1U2FSaVAtR3ZYQXUwaVZUTkxRQlU3cFpuUmV3elBNN3FZS1VtTEdQdEkteXpEX19PQ3pSdnBuS1VYbTAwNnBQQmxhNlhUSFRubkJvV0JreGU4ZUdFeklKVFExcGpPX3daNkxSTnJXcGNfZGVYVmZJWlViRFZxN2dOZ3pMQXVaRWduMA…

ASTRAZEN — Frequently Asked Questions

What is the current share price of AstraZeneca Pharma India Limited (ASTRAZEN)?

As of 2026-07-15 09:52 IST, AstraZeneca Pharma India Limited (ASTRAZEN) trades at ₹8,207.00 on NSE. Its 52-week range is ₹7,765.50 to ₹9,827.50.

What is the market capitalisation of ASTRAZEN?

AstraZeneca Pharma India Limited (ASTRAZEN) has a market capitalisation of ₹20,517.50 Cr on NSE.

What is the P/E ratio of ASTRAZEN?

ASTRAZEN trades at a trailing price-to-earnings (P/E) ratio of 109.41. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 23.75.

Does ASTRAZEN pay a dividend?

AstraZeneca Pharma India Limited (ASTRAZEN) currently offers a dividend yield of 0.39%.

What is the return on equity (ROE) of ASTRAZEN?

ASTRAZEN has a return on equity (ROE) of 21.49%. Its return on capital employed (ROCE) is 25.48%.

Is ASTRAZEN a good stock to buy?

This page provides a data-driven analysis of AstraZeneca Pharma India Limited (ASTRAZEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space